Please login to the form below

Not currently logged in
Email:
Password:

VBP

This page shows the latest VBP news and features for those working in and with pharma, biotech and healthcare.

Cancer Drugs Fund overhaul promises faster access to drugs

Cancer Drugs Fund overhaul promises faster access to drugs

always meant to be a stop-gap measure while the UK developed a value-based pricing (VBP) scheme for medicines. ... The failure of the VBP initiative has meant that the CDF has extended much longer than originally anticipated and it has careened over

Latest news

More from news
Approximately 7 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    of a new drug pricing system, known as value-based pricing (VBP). ... VBP however failed to be approved and the issues around access from 2010 remain today; politically it has also proved difficult for the government to remove this Fund as it has

  • UK market access: The importance of a local value story UK market access: The importance of a local value story

    Finally, there is the spectre of a new drug pricing policy in the guise of value-based pricing (VBP) that is due to come into effect at the start of 2014. ... With VBP, though still an unknown quantity for pharma and, perhaps just as worryingly, the

  • Interview: David Haslam, NICE Interview: David Haslam, NICE

    The new chair of the UK’s NICE discusses navigating the stormy waters of health service reforms, collaborating with pharma and the introduction of VBP. ... Little is known about what this will entail, however, although it has been confirmed that NICE

  • Interview: Cesar Rodriguez, Janssen Interview: Cesar Rodriguez, Janssen

    We are concerned about the implications of the value-based pricing (VBP) system of reimbursement that the government wants to implement from 2014, because as an investor, one of the things

  • The true meaning of market access? The true meaning of market access?

    For example, the UK plans to introduce Value-based Pricing (VBP) for NCEs in 2014, based on a range of cost-effectiveness thresholds, which in turn are based on disease burden, ... We need'parametric' VBP, variable over time. However, there is little

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Playing Mind Games
To give a brief strong direction, we need to ascertain how the brand intends to win attention, how it will engage, what its call to action will be and how...
PM Society Digital Award Finalists
P&P are shortlisted for the ‘Craft in Film’ category at this year’s PM Society Digital Awards...
The Exhibition Hall: Past, Present and Future
As I sit here at another pharma conference, I start to reflect on how they have changed over the years....

Infographics